The importance of animal models in tuberculosis vaccine development

Malaysian Journal of Medical Sciences

Volumn 18, Issue 4, 2011, Pages 5-11

  Acosta, Armando ^a   Nor, Norazmi Mohd ^b   Hernandez Panda, Rogelio ^c   Alvarez, Nadine ^a   Borrero, Reinier ^a   Infante, Juan F ^a   Sarmieto, Maria E ^a  

^a Instituto Finlay   (Cuba)

^b SCHOOL OF HEALTH SCIENCES   (Malaysia)

^c INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Animal models; Animal testing alternatives; Research and development; Tuberculosis; Vaccines

Indexed keywords

BCG VACCINE;

BCG VACCINATION; CATTLE; DRUG COST; DRUG DESIGN; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; EXPERIMENTAL ANIMAL; EXPERIMENTAL GUINEA PIG; EXPERIMENTAL MOUSE; EXPERIMENTAL RABBIT; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; LOW DRUG DOSE; MACACA FASCICULARIS; MACACA MULATTA; NONHUMAN; PRIMATE; PROCESS OPTIMIZATION; REVIEW; TUBERCULOSIS; TUBERCULOSIS CONTROL;

EID: 80053557224     PISSN: 1394195X     EISSN: 21804303     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Levine OS, Bloom DE, Cherian T, de Quadros C, Sow S, Wecker J, et al. The future of immunisation policy, implementation, and fnancing. Lancet. 2011;378(9789):439-448.
2. Schunk MK, Macallum GE. Applications and optimization of immunization procedures. ILAR J. 2005;46(3):241-257.
3. Kanesa-thasan N, Shaw A, Stoddard JJ, Vernon TM. Ensuring the optimal safety of licensed vaccines: A perspective of the vaccine research, development, and manufacturing companies. Pediatrics. 2011;127 Suppl 1:S16-S22.
4. Gerdts V, van Drunen Little, van den Hurk S, Griebel PJ, Babiuk LA. Use of animal models in the development of human vaccines future microbiology. Future Microbiol. 2007;2(6):667-675.
5. Hendriksen C. Three Rs achievements in vaccinology. AATEX [Internet]. 2008 [cited 2011 Sep 5]; 14 Spec Issue; 575-579. Available from: http://altweb.jhsph.edu/bin/q/t/paper575.pdf.
6. Griffn JF. A strategic approach to vaccine development: Animal models, monitoring vaccine effcacy, formulation and delivery. Adv Drug Deliv Rev. 2002;54(6):851-861.
7. Hendriksen C, Arciniega JL, Bruckner L, Chevalier M, Coppens E, Descamps J, et al. The consistency approach for the quality control of vaccines. Biologicals. 2008;36(1):73-77.
8. Davis HL. Novel vaccines and adjuvant systems: The utility of animal models for predicting immunogenicity in humans. Human Vaccin. 2008;4(3):246-250.
9. Metz B, Hendriksen CF, Jiskoot W, Kersten GF. Reduction of animal use in human vaccine quality control: Opportunities and problems. Vaccine. 2002;20(19-20):2411-2430.
10. European Vaccine Manufacturers. Animal welfare and vaccine development [Internet]. Brussel (BE): European Vaccine Manufacturers; 2006 [cited 2011 Sep 5]. Available from: http://www.evm-vaccines.org/pdfs/vaccines_and_animal_welfare_fn.pdf.
11. Hernandez-Pando R, Aguilar D, Hernandez R. The contribution of diverse animal models in the evaluation of new vaccines against tuberculosis. In: Norazmi MN, Acosta A, Sarmiento ME, editors. The art & science of tuberculosis vaccine development [Internet]. 1st ed. Selangor (MY): Oxford University Press; 2010 [cited 2011 Sep 5]. p. 229-345. Available from: http://tbvaccines.usm.my/.
12. McShane H, Williams A. Preclinical evaluation of tuberculosis vaccines. In: Norazmi MN, Acosta A, Sarmiento ME, editors. The art & science of tuberculosis vaccine development [Internet]. 1st ed. Selangor (MY): Oxford University Press; 2010 [cited 2011 Sep 5]. p. 349-373. Available from: http://tbvaccines.usm.my/.
13. Walker KB. Preclinical and clinical development of new tuberculosis vaccines: Regulatory requirements and the transition to phase I and beyond. In: Norazmi MN, Acosta A, Sarmiento ME, editors. The art & science of tuberculosis vaccine development [Internet]. 1st ed. Selangor (MY): Oxford University Press; 2010 [cited 2011 Sep 5]. p. 503-523. Available from URL: http://tbvaccines.usm.my/.
14. Young DB, Perkins MD, Duncan K, Barry CE. Confronting the scientifc obstacles to global control of tuberculosis. J Clin Invest. 2008;118(4):1255-1265.
15. Dye C. Tuberculosis 2000-2010: Control, but not elimination. Int J Tuberc Lung Dis. 2000;4(12 Suppl 2):S146-S152.
16. Al-Kassimi FA, al-Hajjaj MS, al-Orainey IO, Bamgboye EA. Does the protective effect of neonatal BCG correlate with vaccine-induced tuberculin reaction? Am J Respir Crit Care Med. 1995;152(5 Pt 1):1575-1578.
17. Colditz GA, Berkey CS, Mosteller F, Brewer TF, Wilson ME, Burdick E, et al. The effcacy of bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: Meta-analyses of the published literature. Pediatrics. 1995;96(1 Pt 1):29-35.
18. Lanckriet C, Levy-Bruhl D, Bingono E, Siopathis RM, Guerin N. Effcacy of BCG vaccination of the newborn: Evaluation by a follow-up study of contacts in Bangui. Int J Epidemiol. 1995;24(5):1042-1049.
19. Norazmi MN, Sarmiento ME, Acosta A. Recent advances in tuberculosis vaccine development. Curr Resp Med Rev. 2005;1(2):109-116.
20. Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV, et al. Effcacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA. 1994;271(9):698-702.
21. Fine PE. Variation in protection by BCG: Implications of and for heterologous immunity. Lancet. 1995;346(8986):1339-1345.
22. Brewer TF. Preventing tuberculosis with bacillus Calmette-Guerin vaccine: A meta-analysis of the literature. Clin Infect Dis. 2000;31 Suppl 3:S64-S67.
23. Izzo A, Brandt L, Lasco T, Kipnis AP, Orme I. NIH pre-clinical screening program: Overview and current status. Tuberculosis (Edinb). 2005;85(1-2):25-28.
24. Williams A, Hatch GJ, Clark SO, Gooch KE, Hatch KA, Hall GA, et al. Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis. Tuberculosis (Edinb). 2005;85(1-2):29-38.
25. Orme IM. The use of animal models to guide rational vaccine design. Microbes Infect. 2005;7(5-6):905-910.
26. Vordermeier M. Development of cattle tuberculosis vaccines. In: Norazmi MN, Acosta A, Sarmiento ME, editors. The art & science of tuberculosis vaccine development [Internet]. 1st ed. Selangor (MY): Oxford University Press; 2010 [cited 2011 Sep 5]. p. 405-424. Available from: http://tbvaccines.usm.my/.
27. Amanna IJ, Messaoudi I, Slifka MK. Protective immunity following vaccination: How is it defned? Hum Vaccin. 2008;4(4):316-319.
28. McVey DS, Galvin JE, Olson SC. A review of the effectiveness of vaccine potency control testing. Int J Parasitol. 2003;33(5-6):507-516.
29. Higbee RG, Byers AM, Dhir V, Drake D, Fahlenkamp HG, Gangur J, et al. An immunologic model for rapid vaccine assessment-A clinical trial in a test tube. Altern Lab Anim. 2009;37 Suppl 1:19-27.
30. Curlin G, Landry S, Bernstein J, Gorman RL, Mulach B, Hackett CJ, et al. Integrating safety and effcacy evaluation throughout vaccine research and development. Pediatrics. 2011;127 Suppl 1:S9-S15.
31. De Mattia F, Chapsal JM, Descamps J, Halder M, Jarrett N, Kross I, et al. The consistency approach for quality control of vaccines-A strategy to improve quality control and implement 3Rs. Biologicals. 2011;39(1):59-65.
32. Jennings M, Morton DB, Charton E, Cooper J, Hendriksen C, Martin S, et al. Application of the Three Rs to challenge assays used in vaccine testing: Tenth report of the BVAAWF/FRAME/RSPCA/UFAW Joint Working Group on Refnement. Biologicals. 2010;38(6):684-695.
33. De Boo J, Hendriksen C. Reduction strategies in animal research: A review of scientifc approaches at the intra-experimental, supra-experimental and extra-experimental levels. Altern Lab Anim. 2005;33(4):369-377.
34. Rinaudo CD, Telford JL, Rappuoli R, Seib KL. Vaccinology in the genome era. J Clin Invest. 2009;119(9):2515-2525.
35. Poland GA, Oberg AL. Vaccinomics and bioinformatics: Accelerants for the next golden age of vaccinology. Vaccine. 2010;28(20):3509-3510.
36. Hernandez YL, Corona DY, Rodriguez SS, Infante Bourzac JF, Sarmiento ME, Arzuaga NO, et al. Immunization of mice with Mycobacterium tuberculosis genomic expression library results in lower bacterial load in lungs after challenge with BCG. Tuberculosis. 2006;86(3-4):247-254.
37. Yero D, Pajon R, Perez Y, Farinas M, Cobas K, Diaz D, et al. Identifcation by genomic immunization of a pool of DNA vaccine candidates that confer protective immunity in mice against Neisseria meningitidis serogroup B. Vaccine. 2007;25(28):5175-5188.
38. Yero D, Pajon R, Caballero E, Gonzalez S, Cobas K, Farinas M, et al. A novel method to screen genomic libraries that combines genomic immunization with the prime-boost strategy. FEMS Immunol Med Microbiol. 2007;50(3):430-433.
39. Amin N, Aguilar A, Chamacho F, Vazquez Y, Pupo M, Ramirez JC, et al. Identifcation of dengue-specifc B-cell epitopes by phage-display random peptide library. Malaysian J Med Sci. 2009;16(4):4-14.
40. + T cells in human tuberculosis. J Immunol. 2011;186(2):1068-1080.
41. + T cell epitopes from proteins encoded by the specifc RD regions of Mycobacterium tuberculosis for vaccine development and specifc diagnosis. Mol Biol Rep. 2010;37(4):1793-1799.
42. Nguyen Thi LT, Borrero R, Fernandez S, Reyes G, Perez JL, Reyes F, et al. Evaluation of the potential of Mycobacterium smegmatis as vaccine candidate against tuberculosis by in silico and in vivo studies. VacciMonitor. 2010;19(1):20-26.
43. Cataldi A, Bigi F, Norazmi MN, Sarmiento ME, Acosta A. Strategies for new generation vaccine development. In: Norazmi MN, Acosta A, Sarmiento ME, editors. The art & science of tuberculosis vaccine development [Internet]. 1st ed. Selangor (MY): Oxford University Press; 2010 [cited 2011 Sep 5]. p. 186-208. Available from: http://tbvaccines.usm.my/.
44. Rodriguez L, Tirado Y, Reyes F, Puig A, Kadir R, Borrero R. Proteoliposomes from Mycobacterium smegmatis induce immune cross-reactivity against Mycobacterium tuberculosis antigens in mice. Vaccine. 2011;29(37):6236-6241.